Status:
TERMINATED
GW823093C For The Treatment Of Type 2 Diabetes Mellitus
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20-74 years
Phase:
PHASE2
Brief Summary
This study was designed to find dose response and as extension in treatment of GW823093C.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Type 2 diabetes mellitus.
- Managed by diet therapy or receiving treatment with oral anti-diabetic monotherapy (excluding TZD (Thiazolidinediones))
- Exclusion criteria:
- Patients who have metabolic disease judged by investigator as a clinically significance
- Serious cardiovascular disease or serious hepatic disease
Exclusion
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 25 2006
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT00370942
Start Date
April 1 2006
End Date
November 25 2006
Last Update
August 31 2018
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Hokkaido, Japan, 051-0005
2
GSK Investigational Site
Miyagi, Japan, 985-0852
3
GSK Investigational Site
Tokyo, Japan, 130-0004
4
GSK Investigational Site
Tokyo, Japan, 160-0017